Open access · CC-BY
via OpenAlex
Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach
Jeffrey Atkinson, Amy Dokiburra, Hayley Groover, Jonathan P. Godbout, Benjamin M. Segal, Yinan Zhang
Frontiers in Immunology · 2025 · ▲ 5 citations
Abstract
Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disorder of the central nervous system (CNS). Age is the strongest predictor of disease phenotype, with the majority of older adults transitioning to a progressive form marked by irreversible neurological decline. This clinical progression is associated with smoldering, CNS-compartmentalized inflammation and neurodegeneration, for which there are currently no effective disease-modifying therapies. Cellular senescence(definition), characterized by the secretion of pro-inflammatory mediators collectively known as the senescence-associated secretory phenotype (SASP), increases with age and contributes to tissue injury. In MS, neuroinflammation can further promote cellular senescence, creating a self-reinforcing cycle of damage. Senescent microglia have been identified within MS lesions, where their SASP may impair remyelination and exacerbate neurodegeneration. Senolytic agents selectively target and eliminate senescent cells by disrupting anti-apoptotic pathways. In experimental autoimmune encephalomyelitis (EAE), a widely used model of MS, senolytic treatment reduces senescent microglia burden and attenuates disease severity in an age- and drug-dependent manner. Specifically, here we show that middle-aged mice (40-44 weeks) with EAE exhibit improved clinical outcomes and survival following treatment with either dasatinib plus quercetin (D+Q) or navitoclax. Early-phase clinical trials of senolytics(definition) in age-related diseases have demonstrated functional benefits, including improved gait speed in idiopathic pulmonary fibrosis and CNS penetrance in Alzheimer's disease. Translating senolytic therapy to MS will require careful selection of CNS-penetrant and well-tolerated agents, identification of appropriate patient populations, and deployment of responsive biomarkers. Senolytic therapy represents a promising geroscience-based strategy to meet the urgent therapeutic need in progressive MS.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fimmu.2025.1681724
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Atkinson, J., Dokiburra, A., Groover, H., Godbout, J.P., Segal, B.M., & Zhang, Y. (2025). Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach. <em>Frontiers in Immunology</em>. https://doi.org/10.3389/fimmu.2025.1681724
Vancouver
Atkinson J, Dokiburra A, Groover H, Godbout JP, Segal BM, Zhang Y. Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1681724.
BibTeX
@article{jeffrey2025Target,
title = {Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach},
author = {Jeffrey Atkinson and Amy Dokiburra and Hayley Groover and Jonathan P. Godbout and Benjamin M. Segal and Yinan Zhang},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1681724},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
FEBS Journal 2022
Citation only
Targeting cellular senescence with senotherapeutics: senolytics and senomorphics
Journal of Clinical Investigation 2022
Open access · CC-BY
Cellular senescence: a key therapeutic target in aging and diseases
PubMed Central 2019
Preprint · CC-BY
Senolytics and Senostatics: A Two-Pronged Approach to Target Cellular Senescence for Delaying Aging and Age-Related Diseases.
International Journal of Sciences and Innovation Engineering 2025
Open access · CC-BY
Pharmacology of Senolytics: Targeting Cellular Aging in Chronic Diseases
Journal of Translational Internal Medicine 2025
Open access · CC-BY
Senescent cells as a target for anti-aging interventions: From senolytics to immune therapies
Frontiers in Cell and Developmental Biology 2026
Open access · CC-BY